Maintenance therapy in newly diagnosed multiple myeloma: current recommendations.

Item

http://www.wikidata.org/entity/Q38191975

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Maintenance therapy in newly diagnosed multiple myeloma: current recommendations.

@en

type

Item

label

Maintenance therapy in newly diagnosed multiple myeloma: current recommendations.

@en

prefLabel

Maintenance therapy in newly diagnosed multiple myeloma: current recommendations.

@en

P1476

Maintenance therapy in newly diagnosed multiple myeloma: current recommendations.

@en

P2093

Elena Zamagni

http://www.w3.org/2001/XMLSchema#string

Paola Tacchetti

http://www.w3.org/2001/XMLSchema#string

P2860

A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project.

Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients.

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.

Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences

Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome

Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance.

Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma.

P304

581-594

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/14737140.2014.884930

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Michele Cavo

Annamaria Brioli

P577

2014-03-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24579569

http://www.w3.org/2001/XMLSchema#string